Stockchase Opinions

Julien Nono-WomdimTG TherapeuticsTGTXTOP PICKNov 18, 2026

Note that biotech is very risky and very volatile, so tread carefully. In general, you want class-leading drugs, optionality for bigger markets or "other indications", reasonable valuation compared to potential sales.

Its drug treats Multiple Sclerosis, and uses new research to target the appropriate cells (not T cells as before). MS affects ~2.9M people globally. Approaching $1B in revenue. Catalyst is in-home use of the MS drug. No dividend.

(Analysts’ price target is $69.43)
$66.20

Stock price when the opinion was issued

$66.12

As of Nov 18, 2026. Market Open.

biotechnology
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly

The developer of a medication for relapsing MS in patients has seen an 88% reduction in progression after seven years of usage.  It trades at 13x earnings and supports a 100% ROE.  We like that quarterly cash reserves are growing along with cash flow.  We recommend setting a stop-loss at $41, looking to achieve $70 -- upside potential of 30%.  Yield 0%

(Analysts’ price target is $69.70)
BUY

Developing drugs for MS and blood cancers like leukemia. Exciting prospects; boasts promising clinical trial results, especially for their MS drug. Last month, they announced good phase 3 results for that drug which lifted share from the $30's to $50's. Cash flow is fine; they just said they've raised a lot of money.

BUY
A biopharma. Dont sell. Great CEO. It took a long time, but the stock is now paying off.